N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking

Progress in Neuro-psychopharmacology & Biological Psychiatry
E F DominoHideo Tsukada

Abstract

The pros and cons of N-methyl-D-aspartate (NMDA) antagonists as drug models of schizophrenia are discussed in relation to the neuropathology of this complex mental spectrum of diseases. The role of acetylcholine, dopamine, gamma aminobutyric acid, glutamic acid, and serotonin emphasizes that multiple neurotransmitter system abnormalities are involved, even though current drug therapy involves primarily dopamine (D(2))/serotonin (5 HT(2)) antagonists. Only some of the fundamental aspects of schizophrenia are replicated by NMDA receptor antagonists of glutamic acid. Subchronic NMDA antagonism in an animal model results in decreased levels of dopamine in prefrontal cortex and increased D(1) receptor binding. The results of PET studies of schizophrenic patients imply decreased dopamine levels in their prefrontal cortex. Tobacco-smoking schizophrenic patients transiently normalize prepulse inhibition. Nicotine appears to be one factor that may help explain some of these phenomena.

References

Nov 1, 1977·Psychological Medicine·A Carlsson
Jul 1, 1979·Archives of General Psychiatry·D R WeinbergerR J Wyatt
Mar 1, 1976·The American Journal of Psychiatry·E F Domino, S S Khanna
Mar 1, 1976·Archives of Neurology·J J StockardK H Chiappa
Sep 1, 1992·The American Journal of Psychiatry·D C GoffE Amico
Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Feb 22, 1991·Science·T Sawaguchi, P S Goldman-Rakic
Jan 1, 1990·Brain Research. Brain Research Reviews·J W McDonald, M V Johnston
Jun 1, 1990·Trends in Pharmacological Sciences·S Wonnacott
Jan 1, 1989·European Archives of Psychiatry and Neurological Sciences·H Y MeltzerS Matsubara
Feb 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·D H BlackwoodA McInnes
Jan 1, 1987·Schizophrenia Bulletin·R FreedmanR Franks
Sep 1, 1988·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H Y Meltzer
Sep 1, 1988·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S H Snyder
Sep 1, 1988·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A Carlsson
Sep 1, 1988·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D F Klein
Sep 1, 1988·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A J Friedhoff
Jan 1, 1987·Schizophrenia Bulletin·N C Andreasen
Jul 1, 1987·Archives of General Psychiatry·D R Weinberger
Jan 1, 1973·The American Journal of Psychiatry·S H Snyder
Jul 13, 1973·Science·P S HolzmanD W Hughes
Sep 1, 1971·The American Journal of Psychiatry·B SaletuM Saletu
Nov 1, 1968·International Journal of Neuropharmacology·M Miyasaka, E F Domino
Oct 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·E Masterson, B O'Shea
Oct 15, 1982·European Journal of Pharmacology·M E Benwell, D J Balfour
Dec 1, 1995·Archives of General Psychiatry·J W Olney, N B Farber
Dec 1, 1993·The American Journal of Psychiatry·L E AdlerR Freedman
Jan 1, 1993·Schizophrenia Bulletin·D L Braff
Apr 1, 1993·The American Journal of Psychiatry·A H Glassman
Feb 22, 1996·Nature·J S FowlerR Cilento
May 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A K MalhotraA Breier
Jan 1, 1996·Schizophrenia Bulletin·S LeonardR Freedman
Sep 1, 1996·Biological Psychiatry·E F Domino
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·J S FowlerA P Wolf
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·R FreedmanW Byerley
Jun 5, 1998·Schizophrenia Bulletin·L E AdlerR Freedman
Oct 1, 1998·Pharmacopsychiatry·W M Abi-SaabJ H Krystal

❮ Previous
Next ❯

Citations

Jan 19, 2008·Neurotoxicity Research·Yousef Tizabi
Jan 22, 2009·Schizophrenia Bulletin·Klaas E StephanChris D Frith
Jun 4, 2013·Magnetic Resonance Imaging·Jing ZhangMonte S Buchsbaum
Oct 11, 2008·Journal of Psychiatric and Mental Health Nursing·C R MartinJ Atkinson
Jan 24, 2006·Biological Psychiatry·Klaas E StephanKarl J Friston
Aug 14, 2013·Schizophrenia Research·Celso ArangoStephen R Marder
Feb 23, 2013·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Yoshio Kaneko, Matcheri Keshavan
Feb 14, 2007·The International Journal of Neuropsychopharmacology·Amir H RezvaniEdward D Levin
Feb 6, 2015·Therapeutic Advances in Psychopharmacology·Hannah SteedsJames M Stone
Apr 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideo TsukadaEdward F Domino
Apr 28, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideo TsukadaEdward F Domino
Feb 10, 2006·Expert Review of Neurotherapeutics·James M Stone, Lyn S Pilowsky
Feb 29, 2020·Neuropsychiatric Disease and Treatment·Christoph U Correll, Nina R Schooler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here